Materiality
72
m&a
Source
External coverage
Decided
2026-10-01
Lunai Bioworks completed a $20 million preferred issuance to acquire CNS delivery and neurotherapeutic IP. The platform expansion is a modest positive read-through, but benefits remain prospective and the company said Nasdaq compliance determination is pending.